shRNA Knockdown Products
Cellecta’s well-validated and highly cited high-throughput (HT) RNAi-based genetic screening services are ideal for discovery and functional characterization of novel therapeutic targets. To complement this offering, we offer a complete portfolio of shRNA knockdown products.
|Off-the-shelf pooled lentiviral shRNA libraries are available for genome-wide RNAi screens of human cell models and screens of the most annotated signal transduction and cancer-related genes in mouse models|
|To support screening and targeted knockdown studies, we offer a panel of shRNA Control Constructs and shRNA Cloning Vectors
Next-generation sequencing (NGS) kits to easily get read counts on screens using your library of choice are also available.
Cellecta shRNA off-the-shelf products, including libraries, constructs and vectors are available online, for convenient ordering.
Cellecta’s DECIPHER Project has ended. For information, please contact us at firstname.lastname@example.org. To view publications where DECIPHER shRNA Libraries were use, please see our Publications web page and search for DECIPHER.
The DECIPHER RNAi screening platform was an open source project created by Cellecta to provide tools for researchers to perform and analyze comprehensive shRNA knockdown screens and to develop a standardized, yet versatile platform for collecting and comparing results from different studies and labs. The DECIPHER RNAi screening platform aided and continues to aid researchers interested in functional annotation of signaling networks, interpretation of viability screening and expression profiling results, and collaboration with other DECIPHER Project members. Development of the DECIPHER libraries was funded in part by several NIH grants (CA098374, NCRR RR024095, NHGRI HG003355, NCI CA134062, NCI CA141848) and distributed in plasmid form to academic and non-profit researchers under MTA at no charge.
The DECIPHER Project was established by Cellecta, Inc. under collaboration and joint grants with the Fred Hutchinson Cancer Research Center, the Roswell Park Cancer Institute, and The Scripps Research Institute. We would like to acknowledge Dr. Gus Frangou from the FHCRC and Dr. Andrei Gudkov of the RPCI for their invaluable contributions and scientific expertise.